Harnessing Immunotherapy for Rare Cancers: Sandra P. D’Angelo, Alexander N. Shoustari, and Mark Yarchoan will address this topic in a plenary session at the AACR Special Conference on Rare Cancers (July 18-20, Vancouver). Learn more: buff.ly/uT6gl0k #AACRrarecancers26 @markyarchoan.bsky.social

Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week. Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️ gofund.me/f03f47244

Donate to Ethan Neumann Fellowship, organized by Craig Neumann

Ethan Neumann Fellowship Help establish the Dr. Ethan Neumann Memorial Research Fellowshi… Craig Neumann needs your support for Ethan Neumann Fellowship

gofundme.com

New #NEJM report led by Yuxuan Wang In collaboration with Bert Vogelstein and my lab: nejm.org/doi/full/10.... ➡️ctDNA methylation profiling of blood can identify patients with irAEs ➡️irAEs often involve multiorgan tissue injury

Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events | NEJM

In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared.

nejm.org

We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life Just before his died, he officially earned his doctorate and became Dr. Neumann → myarchoan.wixsite.com/yarchoanlabs...

Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...

TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing - Nature Methods

TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.

nature.com

1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma

Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...

medrxiv.org

1/ Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks. 🔗 rdcu.be/emkkd w/ @NeehaZaidi @DrLizJaffee Key takeaways below

Recent advances in therapeutic cancer vaccines

Nature Reviews Cancer - Cancer prevention vaccines have reduced cancer-related mortalities, yet therapeutic cancer vaccine development and clinical translation continues to face challenges. Here,...

rdcu.be

New study led by @danielzabransky.bsky.social lab Older adults respond well to anti-PD1 therapy, despite age-related immune changes 🔗 nature.com/articles/s41... Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells

Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors - Nature Communications

The aging immune system is characterized by changes in immune cell frequencies and functionality. Here the authors report dynamics of age-related divergence of circulating immune responses in patients...

nature.com

Nakazawa et al. studied the peripheral immune profile of a cohort of patients with advanced solid tumors; 54 patients received anti-PD-(L)1 alone and 50 received anti-PD-(L)1 + anti-CTLA-4. bit.ly/42qWx4d   @markyarchoan.bsky.social

Anti-vascular endothelial growth factor enhances immune checkpoint inhibition by reprogramming regulatory T cells into a fragile state @cp-immunity.bsky.social @markyarchoan.bsky.social www.cell.com/immunity/ful... on www.cell.com/immunity/ful...

1/ Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12 📄 www.cell.com/immunity/ful...

Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME

VEGF blockade is known to enhance immune checkpoint blockade (ICB) efficacy, but its precise immunological mechanism remains undefined. Benmebarek et al. reveal that VEGF inhibition drives BAFF- and I...

cell.com

🚨 New manuscript led by Marina Baretti Using #CODEX multiplexed imaging: 🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells) 🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes 🧬 IDH1 mutations → trend ⬆️M2-like mac ▶️ pubmed.ncbi.nlm.nih.gov/39969434/

Our first 2025 paper was published today in JITC Explores the "obesity paradox" in cancer immunotherapy: 1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk) 2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit doi.org/10.1136/jitc...

Excited to share our latest study in Nature Immunology on TLS in #HCC patients treated w/ neoadj ICB: ⏩ TLS linked to improved outcomes ⏩ Novel "involuted" TLS found in tumor regression zones 🔗 nature.com/articles/s41...